Janux Therapeutics, Inc. business relationships

Companies named in Janux Therapeutics, Inc.’s 10-K filed 2026-02-26, and public companies whose annual reports name Janux Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.

Open on the map Full AI visibility profile

AEO visibility: 3.5 / 10
AI naming: <1 / 100
Agent readiness: 0 / 100
AI adoption: 0 / 100

Named in Janux Therapeutics, Inc.’s annual report 3

Merck & Co., Inc. (MRK)Licensor7.7
“Research Collaboration and Exclusive License Agreement with Merck” SEC filing
BRISTOL MYERS SQUIBB CO (BMY)Partner7.7
“In January 2026, we entered into an exclusive license and collaboration agreement with Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types.” SEC filing
Merck & Co., Inc. (MRK)Partner7.7
“Our existing collaborations with Merck and BMS are important to our business.” SEC filing

Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.